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There is perhaps no more important public-health agency in the world than the US Food and Drug Admin-
istration (FDA). Its policies have reshaped 
science and regulation worldwide, giving 
billions of people greater confidence in the 
treatments and foods on which they rely1. 
Yet the agency’s capacity and autonomy — 
and hence the services it renders — are in 
jeopardy. 
The FDA is plagued by threats to its 
power and stability. A vivid example of this 
came last December, when the agency was 
shockingly overruled by Kathleen Sebelius, 
secretary of the Department of Health and 
Human Services (DHHS). She decided, 
with public backing from President Barack 
Obama, that the contraceptive drug Plan B 
would not be available to teenagers under 
the age of 17 without a prescription. 
With this move, Sebelius quashed an 
eight-year decision process, turned back 
more than 70 years of precedent in which 
the agency’s decisions are final, and invited 
future drug-approval contestants to take 
their case directly to the White House. 
At the same time, the agency has little 
jurisdiction over a growing segment of 
the health-care system: dietary supp-
lements. This regulatory gap has had deadly 
consequences. Today, dozens of athletic 
supp lements sold throughout the United 
States contain DMAA (1,3-dimethylamyl-
amine), a stimulant similar to amphetamine 
that was withdrawn from the US pharma-
ceutical market in the 1970s because of 
health concerns.
In 2010, US sales of supplements contain-
ing DMAA exceeded US$100 million. 
DMAA has been linked to increased blood 
pressure and heart rate, panic attacks, 
seizures and stress-induced cardiomyopathy. 
After two deaths last year, the US military in 
December stopped the sale of supplements 
containing DMAA on its military bases. Last 
summer, Health Canada banned DMAA 
from all supplements. 
Amid such developments, many things 
have been going well for the FDA. The 
agency approved a near-record number 
of medicines last year2, and it brings new 
cancer therapies to market quicker than 
its counterpart, the European Medicines 
Agency3. And the FDA has asserted its 
independence at times — under immense 
pressure to continue permitting the drug 
bevacizumab (Avastin) to be marketed for 
metastatic breast cancer, the agency instead 
followed the scientific evidence and revoked 
its approval in November 2011. (Avastin 
remains available for off-label prescription 
and for other cancers.) 
The agency has also demonstrated 
strength and flexibility in its regulation of 
diet pills. It removed sibutramine (Meridia) 
from the markets and did not approve 
rimonabant (which was approved, then 
withdrawn, in Europe), but it has been 
willing to consider new evidence for the diet 
pill Qnexa (a mixture of phentermine and 
topiramate).
Still, the FDA’s recent misfortunes leave 
room for concern. They come at a difficult 
time for US science, society and politics, 
during which the country’s health sector has 
grown weaker. Until Congress acts to boost 
the FDA’s strength and independence, the 
safety and confidence of the world’s citizens 
— as well as medical and technical innova-
tion — remain at risk. I propose a series of 
realistic reforms; they are not a panacea for 
the FDA or for US public health, but they 
could help to preserve the FDA’s place as the 
pre-eminent regulatory agency in the world. 
A STRONGER BODY
The priority in any reform is to strengthen 
the agency. As a first step, we should make 
the FDA a truly independent body. We 
should separate it from the DHHS and give 
the FDA commissioner a six-year term like 
that of the chair of the US Federal Reserve, to 
be deposed only ‘for cause’. Agency respon-
sibilities should be transferred from the 
DHHS secretary to the FDA commissioner, 
which would prevent future repeats of the 
Plan B events by placing all drug-approval 
decisions in the hands of the FDA, not the 
White House. 
In addition, we should reform how the 
agency is funded. At present, the FDA is 
partly supported by application fees that 
drug companies pay each time they submit 
a new drug for approval. The rates and 
terms of these fees — or, more appropriately, 
taxes — are renegotiated every five years, 
creating an opportunity for agency critics 
to hold up funding until their demands are 
met, destabilizing drug development and 
consumer protection. 
Negotiations with companies are 
conducted in secret, with citizens and safety 
advocates effectively excluded, and research 
has shown that drugs approved just before 
the drug-review deadline are more likely 
to encounter safety problems. The list of 
drugs that were approved under deadline 
pressure and then pulled from the market 
Strengthen and 
stabilize the FDA
The US Food and Drug Administration needs to be more 
independent, says Daniel Carpenter.
US sales of dietary supplements exceed US$28 billion a year, but ingredients are unregulated. 
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confidentiality agreements to receive extra 
information not on the label and discarded 
experiments in which unknown ingredients 
impeded subsequent reactions. We are on 
first-name terms with many sympathetic 
scientists who work in research and develop-
ment (R&D) for commercial vendors, and 
who occasionally whisper crucial details off 
the record. 
This secrecy stands in stark contrast to the 
current practices of scientific publication. 
No self-respecting referee or journal would 
accept a research paper in which the authors 
relied on process , substances or sequences 
that they had creat d themselves but did not 
describe i  detail. Yet this is acc ptable 
Earlier this year, my colleagues and I experienced every scientist’s worst nightmare. Twelve months of experi-
ments were deemed useless after we showed 
that a recommended negative control for 
chemically synthesized stretches of RNA 
(microRNA mimics), bought from a bio-
technology company, was inappropriate. 
The sequence was too short, leading to 
results that were impossible to interpret, if 
not just wrong. Because the company didn’t 
reveal much information about the prod-
uct, we only discovered the discrepancy 
fortuitously after testing many microRNAs 
of known sequence, and observing a length-
dependent activity among them. 
This is the worst in a long line of incidents 
that we have experienced as a result of 
the sweeping confidentiality imposed by 
manufacturers of laboratory reagents, who,
for the most part, do not provide full details 
about the contents of their chemicals, 
enzymes or kits. This lack of transparency 
forces researchers to waste time chasing 
information, restricts the types of experi-
ments they can and cannot do and, most 
troublingly, causes them unknowingly to 
perform inappropriate experiments and 
publish misleading results. 
To try to decipher the ingredients of 
commercial products, my colleagues and 
I have tested pH and conductivity, signed 
A recipe for d sas er
Manufacturers of commercial reagents should follow scientific n rms and 
be open about the ingredients of their products, says Anna Git.
Scant information on the myriad kits and reagents purchased by labs can lead researchers to do inappropriate experiments inadvertently.
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Honest work
The plagiarism police deserve thanks for 
defending the honour of the PhD.
Last week, Hungary’s President Pál Schmitt was forced to resign because of plagiarism detected in his 1992 PhD thesis on physi-cal education. Tivadar Tulassay, rector of Budapest’s prestigious 
Semmelweis University, showed admirable courage by standing up to 
the Hungarian establishment to revoke the thesis a few days earlier, 
after experts appointed by the university declared that Schmitt’s thesis 
“failed to meet scientific and ethical standards”. Tulassay, a cardio-
vascular researcher, has since assumed personal responsibility for his 
university’s decision to revoke Schmitt’s title.
Buyer bew r
An inve tigatio  by Nature shows the scale of the market for unapproved stem-cell therapies in 
China. Hype and unrealisti  hope must not b  allowed to und min  genuin  promise.
On  Internet, you can find adve tisements for stem-cell remedi s for every kind of disease or injury. Companies als  promise that the cells will improve a pearance or provide a 
‘rejuvenating’ energy boost. The message — that stem-cell therapies 
need some work, but are an accepted part of medicine — is as clear 
as it is wrong.
But repeat this mantra enough — as it is repeated endlessly online 
— and the promises can start to seem real. In some places, they cer-
t inly ook real. As we reveal on page 149, these ‘cures’ are offered in 
real clinics in China, where real nurses and doctors inject people with 
stem cells in various formulations from various sources — apparently 
convinced that they are helping patients. It looks and feels routine.
China has tried to crack down on unapproved treatments and it is 
not the only place where patients can buy these therapies: stem-cell 
companies also take advantage of gaps in regulation enforcement in 
the United States (see Nature 483, 13–14; 2012). But in China the 
problem is more widespread. 
Promoters of such unproven and unapproved ‘treatments’ liken 
stem-cell therapy to other once-revolutionary therapies, such as organ 
transplantation. Doctors confess that they can’t guarantee that the 
stem cells will work, but they do guarantee that the procedures are safe. 
If they weren’t, say advocates, we would hear about it. So why not try? 
This circular logic makes the apparent infiltration of stem-cell 
technologies into the medical mainstream even more worrisome. The 
more willing patients and medics are to believe, the less they look for 
true clinical data, and the less doctors are forced to produce it. 
Compare the emergence of stem-cell therapies with the introduc-
tion of psychosurgery. Like stem-cell practitioners today, doctors in the 
1930s and 1940s felt that the need for lobotomy was urgent enough 
to bypass the requirement for clinical evidence. Results were reviewed 
selectively, with pacifying brain damage sometimes taken as a stabilizing 
‘cure’ for schizophrenia or nervous disorders. One promoter even share  
the 1949 Nobel Prize in Physiology or Medicine for is part in devel-
oping the procedure. There was no long-term follow-up. In the end, 
doctors mutilated the brains of thousands of patients over the course of 
decades before critics were able to cast enough doubt on lobotomy to 
halt its use. The widespread acceptance made 
it difficult for people to realize that these pro-
cedures were actually doing harm: you don’t 
see a problem if you don’t bother looking for it.
Of course, there is much legitimate research 
into stem cells, including many controlled 
clinical trials. It would be a shame if they were 
tainted by association with historical failures. 
However, judging from Nature’s investigation 
in China, acceptance is already overtaking clinical evidence, with no 
attempt at systematic follow-up of treatments. If stem-cell therapies 
result in cancer or immunological disease, no one will know.
This does not stop people from outside China flocking to the coun-
try to take advantage of the stem-cell therapies offered there and pro-
moted online with glowing endorsements. The clinics are certainly set 
up to make foreigners feel at home. Set aside from the teeming Chinese 
hospitals, stem-cell treatment centres have orderly nurse stations, well-
lit rooms and good bedside care. What is lacking is controlled clinical 
trials, reliable data and government approval. If the dedicated medical 
workers at the clinics don’t see the problems, they need to look harder. 
If they really want to help their patients, they should seek to prove that 
the treatments work, rather than just assuming that they do. ■
“Acceptance 
is already 
overtaking 
clinical 
evidence, with 
no systematic 
follow-up.”
The affair has remarkable parallels with that of Germany’s former 
defence minister, Karl-Theodor zu Guttenberg, who resigned in 
March last year after his own PhD thesis, in law, had been revoked by 
the University of Bayreuth. 
Like Schmitt, zu Guttenberg tried at first to deny plagiarism charges, 
then to underplay them, and he enjoyed powerful political support — 
until protests by a movement of honest PhD holders made his situation 
untenable. Plagiarism hunters have other prominent personalities in 
their sights, and are not necessarily going to be stopped just because a 
thesis is not in electronic form — if suspicion is high, they will digitize 
it themselves. 
In many central European countries, an academic title is a decided 
advantage for a political career; clearly, some ambitious politicians 
think nothing of obtaining such a title by cheating. We can thank the 
plagiarism hunters — whatever their individual motives — for exposing 
dishonesty among those who govern us, and for defending the honour of 
a PhD. The only safe doctorate these days is an honestly acquired one. ■
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Beware the creeping 
cracks of bias 
Evidence is mounting that research is riddled with systematic errors. Left 
unchecked, this could erode public trust, warns Daniel Sarewitz. 
Alarming cracks are starting to penetrate deep into the scientific edifice. They threaten the status of science and its value to soci-ety. And they cannot be blamed on the usual suspects — inad-
equate funding, misconduct, political interference, an illiterate public. 
Their cause is bias, and the threat they pose goes to the heart of research. 
Bias is an inescapable element of research, especially in fields such 
as biomedicine that strive to isolate cause–effect relations in com-
plex systems in which relevant variables and phenomena can never 
be fully identified or characterized. Yet if biases were random, then 
multiple studies ought to converge on truth. Evidence is mounting that 
biases are not random. A Comment in Nature in March reported that 
researchers at Amgen were able to confirm the results of only six of 53 
‘landmark studies’ in preclinical cancer research (C. G. Begley & L. M. 
Ellis Nature 483, 531–533; 2012). For more than a decade, and with 
increasing frequency, scientists and journalists 
have pointed out similar problems. 
Early signs of trouble were appearing by the 
mid-1990s, when researchers began to document 
systematic positive bias i  clinical trials funded 
by the pharmaceutical industry. Initially these 
biases seemed easy to address, and in some ways 
they offered psychological comfort. The prob-
lem, after all, was not with science, but with the 
poison of the profit motive. It could be countered 
with strict requirements to disc ose conflicts of 
interest and to report all clinical trials. 
Yet closer examination showed that the trouble 
ran deeper. Science’s internal controls on bias 
were failing, and bias and error were trending 
in the same direction — towards the pervasive over-selection and 
over-reporting of false positive results. The problem was most provoca-
tively asserted in a now-famous 2005 paper by John Ioannidis, currently 
at Stanford University in California: ‘Why Most Published Research 
Findings Are False’ (J. P. A. Ioannidis PLoS Med. 2, e124; 2005). Evidence 
of systematic pos ive bias was tur ing up in research ranging from basic 
to clinical, and on subj cts rangi g from genetic disease markers to test-
ing of traditional Chinese medical practices. 
How can we explain such pervasive bias? Like a magnetic field that 
pulls iron filings into alignment, a powerful cultural belief is aligning 
multiple sources of scientific bias in the same direction. The belief is that 
progress in science means the continual production of positive findings. 
All involved benefit from positive results, and from the appearance of 
progress. Scientists are rewarded both intellectually and professionally, 
science administrators are empowered and the public desire for a bet-
ter world is answered. The lack of incentives to 
report negative results, replicate experiments or 
recognize inconsistencies, ambiguities and uncer-
tainties is widely appreciated — but the necessary 
cultural change is incredibly difficult to achieve. 
Researchers seek to reduce bias through tightly controlled experi-
mental investigations. In doing so, however, they are also moving far-
ther away from the real-world complexity in which scientific results 
must be applied to solve problems. The consequences of this strategy 
have become acutely apparent in mouse-model research. The tech-
nology to produce unlimited numbers of identical transgenic mice 
attracts legions of researchers and abundant funding because it allows 
for controlled, replicable experiments and rigorous hypothesis-testing 
— the canonical tenets of ‘scientific excellence’. But the findings of such 
research often turn out to be invalid when applied to humans. 
A biased scientific result is no different from a useless one. Neither 
can be turned into a real-world application. So it is not surprising 
that the cracks in the edifice are showing up first in the biomedical 
realm, because research results are constantly put to the practical test 
of improving human health. Nor is it surpris-
ing, even if it is painfully ironic, that some of 
the most troubling research to document these 
problems has c me from industry, precisely 
becau e industry’s profits epend on the results 
of basic biomedical science to help guide drug-
development choices. 
Sci ntists rightly extol th  capacity of researc  
to self-correct. But the lesson coming from bio-
medici e is th t this self-correctio  epends not 
just on competition between res archers, but also 
on the close ti  betwe  science and its appli-
cation that allow society to push back against 
biased and us less results. 
It would therefore be naive to believe that 
systematic error is a pro lem for biomedicin alo e. It is li ely to be 
prevalent in any field that seeks to predi t the behaviour of complex 
systems — economics, ecology, environmental science, epidemiol-
ogy and so on. T  cracks will be there, they are just hard r to spot 
b cau e it is arder to test research r sults t ough direct technologi al 
applications (such as drugs) and traightforward indi at  of desired 
outcomes (such as reduced morbidity and mortality). 
Nothing will corrod  public trust mo  than a creeping awareness 
that scientists are nable to live up to the standards that they have set f r 
themselves. Useful steps to eal with this threa  may range from r duc-
ing the hype from universities and journals about specific projects, to
strengthening collaborations between those involved in fundamental 
research and those who will put the results to use in the real world. There 
are no easy solutions. The first step is to face up to the problem — before 
the cracks undermine the very foundations of science. ■ 
Daniel Sarewitz is co-director of the Consortium for Science, 
Policy and Outcomes at Arizona State University, and is based in 
Washington DC. 
e-mail: dsarewitz@gmail.com
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Scientists may portray themselves as not being motivated by money, but they and the institutions where they work 
respond in spades to financial opportunities. 
Incentives that encourage people to make 
one decision instead of another for monetary 
reasons play an important part in science. 
This is good news if the incentives are right. 
But if they are not, they can cause considerable 
damage to the scientific enterprise.
For instance, cash incentives adopted by 
countries such as China, South Korea and 
Turkey encourage local scientists to sub-
mit papers to high-end journals despite the 
low probability of success. These payments 
have achieved little more than overload-
ing reviewers, taking them away from their 
work, and have increased submissions by 
the three countries to the journal Science by 
46% in recent years, with no corresponding 
increase in the number of publications1. 
Sadly, science is full of incentives gone 
awry. Look no further than expanding PhD 
programmes that produce graduates with 
almost no career prospects, or the growth 
of lab space with no apparent increase in 
productivity. 
The economic rules behind science 
were written without much consideration 
for unintended consequences, but such 
consequences abound because people and 
institutions are so responsive to incentives. 
And in the current economic climate, no one 
can afford to waste time or resources. In a 
world of tight budgets, getting the incentives 
right is more important than ever. 
BAD DIRECTIONS
Consider the financial calculations that 
encourage universities to hire a series of 
postdocs rather than staff scientists. Postdocs 
earn around half to two-thirds of a staff sci-
entist’s salary. They are young, have fresh per-
spectives and new ideas and are temporary, 
so can be let go when budgets decline2. But, 
in reality, postdocs are not cheap: substantial 
resources — both their own and society’s — 
have been invested in training them. 
If a postdoc doesn’t get a research job, 
taxpayers do not get a return on their invest-
ment. Neither does the postdoc: someone 
who did not go to graduate school and 
entered the labour market in 2001 was earn-
ing about US$58,000 in 2008; a first-year 
postdoc who started graduate school in the 
United States in 2001 was making around 
$37,000 in 2008 on graduation3. During 
a three-year postdoc position, a scientist 
gives up more than $60,000 on average in 
return for highly uncertain job prospects. 
And many postdocs will not get a research 
job. There are few faculty openings, and 
limited numbers of research positions in 
government and industry. So even if indi-
vidual postdocs cost less, from a societal 
perspective they can be expensive.
Equally harmful are rules that encourage 
scientists to support graduate students on a 
research assistantship (RA) rather than on a 
training grant, despite evidence that the 
SUMMARY
 ●Science is full of incentives that 
encourage bad financial choices, such 
as expanding labs and hiring too many 
temporary scientists.
 ● These incentives hurt both individual 
scientists and society as a whole, which 
gets minimal return on its investment 
when someone is trained for a field with 
no career prospects.
 ● The way forward is to fix incentives that 
are damaging the system, by considering 
their true social and personal cost.
Perverse 
incentives 
Counterproductive financial incentives divert time 
and resources from the scientific enterprise. We should 
spend the money more wisely, says Paula Stephan.
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VENICE City of Water edges 
closer to becoming a city 
under water p.512
WORLD VIEW Teach young 
scientists how to manage  
their labs p.511
FOOD Fertilizer is the 
best way to feed Africa 
right now p.510
Under surveillance
Global systems for monitoring threats from flu 
need a radical overhaul.
Imagine a global weather and climate forecasting system that collects data regularly in just a handful of countries, and takes measurements elsewhere only during extreme weather events. 
That is what today’s global flu-surveillance system mostly looks like. 
The shortcomings of flu surveillance have long been recognized (see 
Nature 440, 6–7; 2006), but they are attracting renewed attention follow-
ing the creation in labs of strains of the H5N1 avian influenza virus that 
can spread between mammals. The main cited public-health benefit of 
the research is that it will allow for monitoring for such mutations in the 
wild, and give a remote chance of containing an emerging pandemic.
Must try harder
Too many sloppy mistakes are creeping into scientific papers. Lab heads must look more rigorously 
at the data — and at themselves.
for the first time only when problems in published studies are reported.
In private, scientists who run labs in even the most prestigious uni-
versities admit that they have little time to supervise and train all their 
students. Institutions such as the European Molecular Biology Labora-
tory in Heidelberg, Germany, have maximum lab sizes for this reason. 
Funding agencies should require grant applicants to indicate lab size 
and offer adequate supervision. As is the case in commercial compa-
nies, larger labs should introduce formal 
training and a management hierarchy, with 
more experienced postdocs and research 
associates required to sign off data and 
experiments if PIs cannot do so themselves. 
What can journal editors and referees 
do? Sloppiness is sometimes caught, but 
so much must be taken on trust. Journals 
should certainly offer online commenting, 
so that alert readers can point out errors. 
Where comments or corrections appear 
in other journals, these should be linked 
from the original paper — as the Comment authors recommend.
There should also be increased scope to publish fuller results from 
an experiment, and subsequent negative or positive corroborations. 
There is an opportunity here for ‘minimum threshold’ journals, such 
as PLoS ONE and Scientific Reports. Editors and referees cannot be 
expected to divine when only positive data are included and inconven-
ient results left out, but journals should encourage online presentation 
of the complete picture. And scientists should offer it. The complete 
picture is, after all,  what this science of ours strives to provide. ■
Science: Branch of knowledge or study dealing with a body of facts or truths systematically arranged. So says the dictionary. But, as most scientists appreciate, the fruits of what is called science are 
occasionally anything but. Most of the time, when attention focuses 
on divergence from this gold (and linguistic) standard of science, it is 
fraud and fabrication — the facts and truth — that are in the spotlight. 
These remain important problems, but this week Nature highlights 
another, more endemic, failure — the increasing number of cases in 
which, although the facts and truth have been established, scientists 
fail to make sure that they are systematically arranged. Put simply, 
there are too many careless mistakes creeping into scientific papers 
— in our pages and elsewhere.
A Comment article on page 531 exposes one possible impact of such 
carelessness. Glenn Begley and Lee Ellis analyse the low number of can-
cer-research studies that have been converted into clinical success, and 
conclude that a major factor is the overall poor quality of published pre-
clinical data. A warning sign, they say, should be the “shocking” number 
of research papers in the field for which the main findings could not be 
reproduced. To be clear, this is not fraud — and there can be legitimate 
technical reasons why basic research findings do not stand up in clini-
cal work. But the overall impression the article leaves is of insufficient 
thoroughness in the way that too many researchers present their data.
The finding resonates with a growing sense of unease among 
specialist editors on this journal, and not just in the field of oncology. 
Across the life sciences, handling corrections that have arisen from 
avoidable errors in manuscripts has become an uncomfortable part 
of the publishing process.
The evidence is largely anecdotal. So here are the anecdotes: un related 
data panels; missing references; incorrect controls; un declared cosmetic 
adjustments to figures; duplications; reserve figures and dummy text 
included; inaccurate and incomplete methods; and improper use of 
statistics — the failure to understand the difference between technical 
replicates and independent experiments, for example. 
It is usually the case that original data can be produced, mistakes 
corrected, and the findings of the corrected research paper still stand. 
At the very least, however, there is too little attention paid and too many 
corrections, which reflect unacceptable shoddiness in laboratories that 
risks damaging trust in the science that they, and others, produce. 
The situation throws up many questions. Here are three of them. 
Who is responsible? Why is it happening? How can it be stopped?
The principal investigators (PIs) of any lab from which the work 
originates, especially if their names are on the paper, have an absolute 
and unavoidable responsibility to ensure the quality of the data from 
their labs, even if the main work is done by experienced postdocs. 
Officially, postdocs and graduate students are still in training, and it is 
the PI’s job to make sure they are properly trained — in statistics and 
appropriate image editing, for a start. It is unacceptable for lab heads 
—who are happy to take the credit for good work — to look at raw data 
“Handling 
corrections that 
have arisen from 
avoidable errors 
in manuscripts 
has become an 
uncomfortable part 
of he publishing 
process.”
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for British scientists. These, and many other issues he raised, such as 
increasing scientists’ interactions with industry, commerce and the 
media, and resisting the politicization of climate-change research, are 
relevant throughout the world and not just in Britain.
All the more reason not to misinterpret Nurse’s insistence on a separa-
tion of science and politics: as he put it, first we need the science, then the 
politics. What Nurse rightly warned against is the intrusion of ideology 
into the interpretation and acceptance of scientific knowledge as, for 
example, in the Soviet Union’s support of the anti-Mendelian biology 
of Trofim Lysenko. Given recent accounts of political interference in 
climate research in the United States (N. Oreskes and E. M. Conway 
Nature 465, 686; 2010), this is a timely reminder.
But it is easy to render this equation too simplistically. For exam-
ple, Nurse also cited the rejection by Adolf Hitler of Albert Einstein’s 
relativistic physics as ‘Jewish physics’. But that is not quite how it was. 
‘Jewish physics’ was a straw man invented by the anti-Semitic and pro-
Nazi physicists Johannes Stark and Philipp Lenard, partly because of 
professional jealousies a d grudges. Th  Nazi leaders were, however, 
largely indifferent to what looked like an academic squabble, and in the 
end lost interest in Stark and Lenard’s risible ‘Aryan physics’ because 
they needed a physics that actually worked.
That is one reason to be sceptical of the co mon claim, repeated 
by Nurse, that science can flourish only in a free society. Historians 
of science in Nazi Germany such as Kristie Macrakis (in her book 
Surviving the Swastika) have challenged this assertion, which is not 
made true simply because we would like it to be so. Authoritarian 
regimes are perfectly capable of putting pragmatism before ideology. 
The scientific process itself is n t impeded by state control in China 
— quite the contrary — and the old canard that Chinese science lacks 
innovation and daring is now transparently nonse se. During the cold 
war, some Soviet science w s vibrant and bold. Even the most notori-
ous example of state repr ssi n of scienc  — the trial of Galileo — is 
apt to be portrayed too simplistically as a conflict of faith and reason 
rather than a collision of personalities and circumstances (none of 
which exonerates Galileo’s scandalous persecution).
There is a more compelling lesson to be drawn from Nazi Germany 
that bears on Nurse’s themes: although political (and religious) ideol-
ogy has no place in deciding scientific ques-
tions, the practice of science is inherently 
political. In that sense, science can never 
come before politics. Scientists everywhere 
enter into a social contract, not least because 
they are not their own paymasters. Much, if 
not most, scientific research has social and political implications, often 
broadly visible from the outset. In times of crisis (like the present), sci-
entists must respond intellectually and professionally to the challenges 
facing society, and not think that safeguarding their funding is enough.
The consequences of imagining that science can remain aloof from 
politics became acutely apparent in Germany in 1933, when the con-
sensus view that politics was, as Heisenberg put it, an unseemly “money 
business” meant that most scientists saw no reason to mount concerted 
resistance to the expulsion of Jewish colleagues — regarded as a political 
rather than a moral matter. This ‘apolitical’ attitude can now be seen as a 
convenient myth that led to acquiescence in the Nazi regime and made 
it easy for German scientists to be manipulated. It would be naive to 
imagine that only totalitarianism could create such a situation.
The rare and most prominent exception to apolitical behaviour was 
Einstein, whose outspokenness dismayed even his principled friends 
the German physicists Max Planck and Max von Laue. “I do not share 
your view that the scientist should observe silence in political matters,” 
he told them. “Does not such restraint signify a lack of responsibility?” 
There was no hint of such a lack in Nurse’s talk. But we must take care 
to distinguish the political immunity of scientific reasoning from the 
political dimensions and obligations of doing science. ■
“The practice 
of science is 
inherently 
political.”
Gold in the text? 
Publishers and scientists should do more to foster 
the mining of research literature by computer. 
Whether from the petabytes of data produced by the Large Hadron Collider, or the hundreds of millions of bases in the human genome, much scientific analysis nowadays 
relies on computer  to pull out meaning from swathes of data. But one 
vas  stor  of information, the res arch literature, ha  so far seemed 
immune to computer analysis. By and large, articl s exist only in 
formats designed for humans to read — such as thi  paragraph. 
Text-mining aims to break dow  this b rrier. Using natural-language-
processing concepts honed over the past 30 years, computer programs 
ar  starting to pull out information from plain t xt, ncluding patents 
and research articles. Right ow, the software requires highly skilled 
op rators, but in the next decade it ight transfor  the way scientists 
read the literature. Text-miners hope to make scientific discoveries by 
scouring hundreds of research papers for associations and connections 
(such as between drugs and side effects, or genes and disease pathways) 
that humans reading each paper individually might not notice.
The promise is yet to be backed up with concrete examples of scien-
tific success — although in the pharmaceutical industry, text-mining 
companies are already working with researchers to speed up drug 
discovery. But academics are struggling to even run experiments — 
because publishing licences do not let them text-mine research papers, 
and publishers are slow to respond to text-mining requests. Fed up 
after two years of negotiations, one team of researchers is launching a 
public website to log publishers’ responses (see page 134). 
There is no doubt that a completely open research literature would 
make it easier to demonstrate how such machine-reading can lead to 
scientific discovery. But the question is how to make progress today, 
when much research lies behind subscription firewalls and even ‘open’ 
content does not always come with a text-mining licence (including 
83% of the ‘free’ research in the PubMedCentral online archive).
Publishers should agree that scientists who have already paid for 
access to research papers may text-mine content at no extra cost and 
publish their findings — as long as their doing so does not breach the 
original firewall. Publishers can have no claim on the data in articles, 
only on the way in which the articles have been edited and formatted. 
They should make their text-mining policies clear and consider fol-
lowing the example of the journal Heredity, which says it is “seeking to 
encourage text-mining experiments”. (Its publisher, Nature Publishing 
Group, which also publishes this journal, says that it does not charge 
subscribers to mine content, subject to contract.)
On the other hand, text-miners need to make a better case for their 
technology. They say they are in a catch-22 situation — how can they 
demonstrate the benefits if they aren’t allowed to run experiments on 
the literature? Instead, they text-mine abstracts, usually by picking out 
key words — a pale shadow of what full-text-mining might offer. Casey 
Bergman at the University of Manchester, UK, is chronicling projects 
that have tried to text-mine the available PubMedCentral content (see 
go.nature.com/2pqp8g) and finds very few examples — suggesting that 
text-miners are reluctant even to mine the corpus of free content.
Publishers point out that they receive few text-mining requests, so 
the field can’t be very hot. So unless text-miners start to make full use 
of the content that is available, and request more 
access to published content — while always 
being clear about how their project will 
benefit science — the unsatisfactory impasse 
will continue. ■
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CANADA It is time to allow 
scientists to speak to  
the press p.6
The gr at beyo
Progress on rare genetic diseases shows the 
medical valu  of outliers.
“Treasure your exceptions! When there are none, the work gets so dull that no one cares to carry it further. Keep them always uncovered and in sight. Exceptions are like the 
rough brickwork of a growing building which tells that there is more 
to come and shows where the next construction is to be.” Geneticist 
William Bateson offered this advice in 1908, around the dawn of mod-
ern genetics following the rediscovery of Gregor Mendel’s pea plant 
experiments, and it remains sound today.
Every empiricist must contend with exceptions to the rule, which can 
illuminate research in unpredictable ways. Bateson was urging vigilance 
in observing rare offspring of plants and animals, which may point to 
new phenomena that can inform us about the broader biological con-
text. The same is true for rare diseases, which often have a genetic basis. 
This being a leap year, the extra day, 29 February, was designated 
Rare Disease Day. It aims to give a voice to the families of millions of 
exceptional children who are born each year with a rare or undiag-
nosed disease. Liddle syndrome and Tangier disease, for example, 
Th  darker id  of te  c l s
An investigation by Nature has found that patie ts in Texas re receiving unproven stem-cell 
treatments. The state a d the company involved need to ensure that th y follow FDA guidelin .
Stem cells offer the hope that one day they will be able to cure a huge range of disorders. But too many people are promising those cures to patients now, long before there is any evidence that they 
work. These claims are potentially misleading at best, and at worst 
could be downright harmful. 
This week, Nature raises important questions about one company 
that works with adult stem cells: Celltex Therapeutics in Houston, 
Texas. Nature’s investigation, reported on page 13, suggests that the 
company has supplied adult stem cells to Texas doctors who offer 
unproven treatments to patients, and that the company is involved in 
these treatments. One doctor claims that the treatments are part of a 
clinical study run by Celltex and that the company pays him US$500 a 
time to inject the cells into patients, who are charged up to $25,000 for 
a course. The US Food and Drug Administration (FDA) considers it 
to be a crime to inject unapproved adult stem cells into patients. David 
Eller, chief executive of Celltex, denies that the company is involved in 
treatment procedures, but would not comment on Nature’s findings 
about how its cells are used or answer questions about them.
Celltex has the backing of state governor Rick Perry, who has tried 
adult-stem-cell treatments himself. And the company recently recruited 
Glenn McGee, editor-in-chief of the American Journal of Bioethics, to 
be its president of ethics and strategic initiatives. McGee, whose move 
from the academic world to industry sparked a controversy over a per-
ceived conflict of interest (see Nature 482, 449–450; 2012), promises 
that Celltex will set up and run clinical trials, and will do so according to 
strict ethical standards. But he too would not answer Nature’s questions 
on whether the company knew about the unapproved clinical use of its 
stem cells or whether he considered such activity to be ethical and legal. 
There is an ethical paradox here. How can Celltex propose clinical 
trials for stem-cell treatments while at the same time it is, according to 
a doctor involved, paying physicians to use those treatments — or sup-
plying cells to doctors who would no doubt use them — in the clinic? 
Shouldn’t clinical trials be done before a treatment is given to paying 
patients? Conversely, if a treatment is known to be safe and effective 
enough to be prescribed routinely, and for a sizeable fee, what is the 
point of doing a costly clinical trial?
The questions do not stop at Celltex. The governor-appointed Texas 
Medical Board is set to launch regulations in April to tighten controls 
on the use of ‘investigational agents’ — such as stem cells that do not 
have FDA approval. But the board is simultaneously offering an alter-
native route by proposing that those who want to use adult-stem-cell 
treatments need either FDA approval or simply the approval of a local 
institutional review board.
Texas officials should take the FDA’s regulatory power over stem cells 
more seriously. In its discussions, the state’s medical board revisited 
the well-trodden ground of whether adult-stem-cell procedures — in 
which cells are taken from a patient, processed and cultured, before 
being reintroduced — should be under FDA jurisdiction, or whether 
they are akin to simple skin grafts from one part of the body to another, 
which do not require validation in an FDA-approved clinical trial. 
The FDA can help to clarify these matters. A sensible first step in the 
new state regulations would be a requirement for any firm that plans to 
inject processed stem cells into patients to contact the FDA, which can 
advise on whether federal rules — the same 
federal rules that have already been used to 
arrest stem-cell practitioners and to stop a 
company pus ing un pproved treat ents 
elsewhere — apply to what they are doing. 
Once past that step, Texas could move on to 
develop its own safety regulations. 
If the Texas Medical Board were to act 
according to its stated pledge to protect patients, then it would make 
clear the need for clinical validation of adult stem cells before use and 
would rescind the medical licences of any doctors in breach of rules on 
using unapproved treatments. If Celltex truly wants to help patients, 
then it should refuse to supply stem cells for medical procedures until 
those procedures are properly proven to be effective. And if the com-
pany is serious about demonstrating clinical effectiveness itself, then 
it should start by contacting the FDA about what needs to be done. ■
“Texas officials 
should take the 
FDA’s regulatory 
power over 
stem cells more 
seriously.”
WORLD VIEW The rights 
and wrongs of social 
neuroscienc .7
DISCOVERY Seven new 
species of limbless 
amphibians p.8
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The injections came without warning or explanation. As a low-ranking soldier in the Guatemalan army in 1948, Federico Ramos was preparing for weekend leave one Friday when he was ordered to report to a clinic run by US doctors.
Ramos walked to the medical station, where he was given an 
injection in his right arm and told to return for another after his leave. 
As compensation, Ramos’s commanding officer gave him a few coins 
to spend on prostitutes. The same thing happened several times during 
the early months of Ramos’s two years of military service. He believes 
that the doctors were deliberately infecting him with venereal disease.
Now 87 years old, Ramos says that he has suffered for most of his life 
from the effects of those injections. After leaving the army, he returned to 
his family’s remote village, on a steep mountain slope northeast of Gua-
temala City. Even today, Las Escaleras has no electricity or easy access to 
medical attention. It wasn’t until he was 40, nearly two decades after the 
injections, that Ramos saw a doctor and was diagnosed with syphilis and 
gonorrhoea. He couldn’t pay for medication. 
“For a lack of resources, I was here, try-
ing to cure myself,” says Ramos. “Thanks to 
God, I would feel some relief one year, but 
it would come back.” Over the decades, he has endured bouts of pain 
and bleeding while urinating, and he passed the infection onto his wife 
and his children, he told Nature last month in an interview at his home. 
Ramos’s son, Benjamin, says that he has endured lifelong symptoms, 
such as irritation in his genitals, and that his sister was born with cankers 
on her head, which led to hair loss. Ramos and his children blame the 
United States for their decades of suffering from 
venereal disease. “This was an American experi-
ment to see if it caused harm to human beings,” 
says Benjamin.
Ramos is one of a handful of survivors from 
US experiments on ways to control sexually 
FIRST, DO HARM
In the 1940s, US doctors deliberately infected thousands of 
Guatemalans with venereal diseases. The wound is still raw. 
B Y  M A T T H E W  W A L T E R
US doctors experimented 
on patients with psychiatric 
disorders without consent.
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Two months after we started a blog that tracks scientific retractions — Retraction Watch — in 2010, one of 
us (A.M.) told The New York Times that we 
weren’t sure we would have enough mate-
rial to post with any regularity. That con-
cern turned out to be unfounded — in just 
16 months, we have written about some 
250 retractions. Little did we know that, in 
scientific publishing, 2011 would become 
the Year of the Retraction.
Here’s what grabbed everyone’s atten-
tion: retractions have increased 15-fold 
over the past decade, while the number of 
papers has risen by less than 50% (see Nature 
478, 26–28; 2011). It is not clear why, and 
it is always dangerous to draw too many 
conclusions from what is a relatively rare 
occurrence — some 300 retractions among 
1.4 million papers published annually. About 
90 retractions, after all, have come from one 
author, Joachim Boldt, a German anaesthe-
siologist, largely because he failed to obtain 
the appropriate approvals for his research. 
Still, it is clear that software that detects 
plagiarism has played a part in the retraction 
spike, as has the larger number of eyeballs on 
papers, thanks to the Internet. It is important 
to point out that an increase in retractions 
isn’t necessarily a bad thing, because they 
correct the scientific record. But the greater 
visibility of papers and retractions today 
adds to the evidence revealing why editors 
need to handle retractions more transpar-
ently. In turn, researchers need to stop 
emphasizing the paper so much.
What is needed, instead, is a system of 
publication that is more meritocratic in its 
evaluation of performance and productivity 
in the sciences. It should expand the record 
of a scientific study past an individual 
paper, including additional material such as 
worthy blog posts about the results, media 
coverage and the number of times that the 
paper has been downloaded. 
The expanded model would also make 
it crystal clear to readers when a paper has 
been corrected or retracted, and why. This 
would start with better notices from jour-
nals to explain those changes. Take the 
retraction1 of a paper earlier this year in The 
EMBO Journal by immunologist Silvia Bul-
fone-Paus. Bulfone-Paus was at the centre of 
a misconduct scandal at the Research Cen-
tre Borstel in Germany, where she stepped 
down as lab head under pressure in 2010. 
The Borstel board found her “ultimately 
responsible” for the misconduct in her lab 
and for failing to deal with it in a timely and 
open manner. (Bulfone-Paus has made few 
public statements about the case, but she 
has noted that her results were confirmed 
by other researchers.) In 2011, journals 
retracted 13 of her published articles, the 
stated reasons varying from detailed expla-
nations such as “evidence of data manipula-
tion in Fig. 2C, 4B, and 9, a clear violation 
of ASM’s ethical standards”2, to the wholly 
unhelpful “This article has been withdrawn 
by the authors”. 
Lines like the latter make us want to pull 
out whatever hair we have left on our heads. 
Journal readers should find them similarly 
frustrating. But we singled out this particu-
lar notice for concern not because it said too 
little, but because, in our view, it allowed the 
authors to say too much. 
TOO LAISSEZ-FAIRE?
The EMBO Journal’s notice1 also included 
this: “The authors declare that key experi-
ments presented in the majority of these fig-
ures were recently reproduced and that the 
results confirmed the experimental data and 
the conclusions drawn from them.”
The statement from Bulfone-Paus and 
her colleagues described new data and sig-
nalled to readers that they could still rely on 
the original paper, even though it had been 
retracted. It suggested that the journal stood 
behind the statement. But when we asked the 
editor whether that was the case, we were told: 
“We did not formally investigate this case at 
the journal and we have not seen this data, as 
it does not affect the retraction.”3
We’ve seen a similar lack of close editorial 
review in correction notices, too. Two recent 
corrections in Nature, and one in Nature 
Medicine, which can only be described 
as massive, describe in painful detail the 
number of errors in the original papers. 
In one, images were mp operly labelled 
and cropped, requiring a solid page of text 
to explain the changes and how they affect 
the paper, while another acknowledged that 
images had been manipulated, which was 
“not acceptable”. 
One of those correction notices, published 
on 28 September of this year, included this 
line: “We have also included results from 
a new, reproduced experiment recently 
performed with an additional cohort of 
animals that shows exactly the same results.”4 
Including new data in a correction notice 
seemed unusual, so we wanted to know if 
that line had been subject to peer review. 
As we reported on our blog5, the journal 
wouldn’t say, responding only that peer 
review is confidential, and that we should 
talk to the authors — who never responded 
to our requests for comment.
We don’t mean to question the claims in 
The paper  
is not s c ed
Peer review continues long after a paper is published, 
and that analysis should become part of the scientific 
record, say Adam Marcus and Ivan Oransky.
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Hypocritical oat s 
Hist ry judges som  research as unethical, 
despite approval at the time.
Ethical boundaries for xperiments on humans can be stated very simply. “The limits of justifiable experimentation upon our fel-low creatures are well and clearly defined,” Canadian physician 
William Osl r, one of the grand old men of US medicine, wrote more 
than a centu y ago. “F r man absolute safety and full consent are the 
conditions whi h make such tests allowable.”
Although US standards have evolved, the concepts of informed con-
sent and safety still underpin research on humans. How, then, could 
leading health officials in the Unit d States approve a set of barbarous 
experiments in the 1940s, in which government physicians intention-
ally infect d hundreds of people in Guatemala with venereal diseases?
The people were labelled v lunteers, but evidence suggests that they 
did not provide consent. And as the News Feature on page 148 shows, 
records i dicate that some of the people exposed to syphilis, gonorrhea 
nd chancroid s bs quently went untreated.
Such recklessness seems abhorrent now, but this is far from an 
isolated case. In 1941, US phy ician William Black infected children, 
including a 12-month-old baby, with the herpes virus. When Black 
submitted his pap r to the Journal of Experimental Medicine, it was 
rejected. Francis Peyto  Rous, the journal’s editor, told Black that his 
work was “an abuse of power”. N netheless, the paper was published 
soon after by the Journal of Pediatrics.
And Rous w s less concer ed about a study in which residents of a 
psychiatric hospital in Michigan were infected with influenza, even 
t ough it seems that at least some of the patients could not give their 
cons nt. It might be tempting to explain away such research abuses as 
the work of rogue scientists, but the Michigan study was conducted 
by a leading researc er of the time, Thomas Francis Jr, and his young 
colleague, Jonas Salk, who we t on to develop the polio vaccine. 
And two decades later, in 1963, a team run by Chester Southam 
injected tumour cells into extremely infirm patients at the Jewish 
Hospital for Chronic Disease in New York without informing them 
that the shots contained cancer. Southam was later put on probation 
by the New York State medical licensing board, but many researchers 
defended the work and he was later elected president of the American 
Association for Cancer Research. 
What kind of work deemed as accepted today will be denounced by 
future generations? The question is one that all researchers should bear 
in mind, because history may judge them more harshly than their peers 
do. One example could be denial of treatment to sick people through 
the use of placebos in clinical trials and the ways in which some of these 
trials are carried out in developing nations, amid accusations of abuse of 
poor, uneducated participants. Broadening to other types of research, 
attitudes to work on embryonic stem cells may harden. And future 
generations may extend the protection currently in place for humans 
to cover other species, such as chimpanzees. 
In the case of chimpanzees, Gabon and the United States are the only 
nations known to still use them for research, and a committee of the 
US National Research Council last year recommended that the United 
States should sharply limit their use, but stopped short of calling for a 
complete ban. Meanwhile, some researchers have been able to avoid 
bans in their own countries by travelling to the United States. Since 
2005, foreign scientists have conducted at least 27 experiments at US 
chimpanzee centres (see Nature 474, 268–271; 2011).
There is, of course, clear water between the Guatemalan 
experiments and chimpanzee research. The Guatemala research was 
illegal, even in the 1940s, and most of the data did not prove useful 
and went unpublished. Still, as with research on embryonic stem cells, 
there is considerable debate about the ethics of using chimpanzees as 
experimental subjects. In these and other cases, nations would do well 
to heed some of the lessons that emerged from the investigation of the 
experiments in Guatemala. Governments and 
other funders of research must exert full over-
sight, provide as much transparency as possible 
and ensure that regulations are clear, strong and 
evolve with the times. ■
As discussed on page 139, a study led by scientists from the US 
National Oceanic and Atmospheric Administration (NOAA), head-
quartered in Washington DC, and the University of Colorado in Boulder 
looked at methane and other emissions from a natural-gas field north of 
Denver, where fracking methods are used to open up sand formations.
They estimated cumulative emissions from the field using not indus-
try reports or conceptual models, but concentrations of pollutants in air 
samples. This is important because the atmosphere does not misrepre-
sent data or make mistakes; nor does it bend to ideology or political will.
The data suggest that methane emissions from natural-gas operations 
could be substantially higher — and so be worse for global warming — 
than was thought. At works in the Denver-Julesburg Basin, methane 
emissions were roughly double the official estimate. 
This will by no means settle the debate. The NOAA scientists had to 
make assumptions to convert atmospheric data to cumulative emis-
sions from a vast energy complex. They readily acknowledge substan-
tial uncertainty in their calculations, and estimate that between 2% 
and 8% of the methane produced from wells in the Denver-Julesburg 
Basin is lost to the atmosphere, with a best guess of 4%. 
These numbers, which are higher than estimates from Cornell and 
the US Environmental Protection Agency (EPA), should serve as a red 
flag to the gas industry, policy-makers and the academic community. 
Researchers will need to confirm the findings, reduce the uncertain-
ties and determine emissions from other locations. But the issue clearly 
warrants attention. The study should also be a reminder that although 
it is necessary for the industry to collect data on its practices and run 
calculations, independent monitoring and verification are needed.
More generally, the study further complicates understanding of 
what is considered the world’s cleanest fossil fuel. Many in industry and 
science have talked about using gas as a bridge fuel for the transition 
from coal to cleaner sources of electricity, but the picture is unclear. 
In many places, including the United States, gas-fired electricity is 
likely to be significantly cleaner than coal in 
terms of carbon emissions even with the extra 
methane leakage — if only because newer 
gas-fired plants are much more efficient than 
the behemoths that provide most coal-fired 
electric generation. By contrast, a model-
ling study by Tom Wigley, a climate scientist 
at the US National Center for Atmospheric 
Research in Boulder, last year found that switching from coal to natural 
gas would actually increase global temperatures for decades, by reduc-
ing emissions of pollutants that reflect solar radiation back into space 
(T. M. L. Wigley Climatic Change 108, 601–608; 2011). In the end, 
natural gas might be preferable to coal just because it reduces harmful 
air pollution. But the climatic benefits are murky at best.
The good news is that the natural-gas industry has the capacity to 
reduce methane leakage by cleaning up its operations. Technologies 
are already available to capture methane during fracking rather than 
venting it into the atmosphere when bringing a gas well online. As it 
happens, the EPA is currently considering mandatory regulations that 
encourage such activities by limiting various pollutants from natural-
gas operations. These regulations would indirectly reduce methane 
emissions, and the EPA must press forward. ■
“Emissions from 
natural-gas 
operations could 
be substantially 
higher than was 
thought.”
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R i  t ndard f   
precli ical ca c r a c
C. Glenn Begley nd L e M. Ellis propose how metho s, publications nd  
incentives must change if patients are to benefit.
Efforts over the past decade to characterize the genetic alterations in human cancers have led to a better 
understanding of molecular drivers of this 
complex set of diseases. Although we in the 
cancer field hoped that this would lead to 
more effective drugs, historically, our ability 
to translate cancer research to clinical suc-
cess has been remarkably low1. Sadly, clinical 
trials in oncology have the highest failure 
rate compared with other therapeutic areas. 
Given the high unmet need in oncology, it 
is understandable that barriers to clinical 
development may be lower than for other 
disease areas, and a larger number of drugs 
with suboptimal preclinical validation will 
enter oncology trials. However, this low suc-
cess rate is not sustainable or acceptable, and 
investigators must reassess their approach to 
translating discovery research into greater 
clinical success and impact.
Many factors are responsible for the high 
failure rate, notwithstanding the inher-
ently difficult nature of this disease. Cer-
tainly, the limitations of preclinical tools 
such as inadequate cancer-cell-line and 
mouse models2 make it difficult for even 
Many landmark findings in preclinical oncology research are not reproducible, in part because of inadequate cell lines and animal models.
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Guest	  post:	  Time	  to	  bring	  human	  genome	  sequencing	  into	  the	  clinic	  
02/16/2012	  
	  
THIS WEEK
HIGGS Would a boson by 
another name smell as 
sweet? p.374
WORLD VIEW Rio summit 
demands a different 
science approach p.375
TASTELESS Bottlenose 
dolphins get little flavour 
from food p.377
Flight risk 
As the campaign against animal research 
intensifies, so must the response.
Picture a crowd of scientists waving placards plastered with photographs of stroke victims and sufferers of Parkinson’s disease. They are demonstrating outside the corporate head-
quarters of British Airways, Lufthansa and Delta, demanding that the 
airlines stop impeding the biomedical research that could deliver big 
advances against these and other diseases.
Seem far-fetched? Maybe. But if scientists want continued access 
to animals as research models, they will have to appear on the front 
line with every bit as much visibility, determination, organization and 
persistence as animal-rights activists now muster. 
In a renewed campaign targeting transportation companies, pro-
testors have found a public pressure point so effective that only a few 
major airlines still agree to transport non-human primates bound for 
research labs (see page 381). Nor is the focus confined to primate 
transportation: earlier this year, the last ferry company that was willing 
to carry research rodents into the United Kingdom stopped doing so. 
Such blocks, scientists warn, could shift much animal work to coun-
tries where regulations are more lax.
But there is a silent majority for whom the activists do not speak. 
Incidental benefits
Scientists who screen the genes of volunteers for research should tell participants if they  
find information relevant to their health.
screw you will probably be able to get a copy of the data they need to 
do so, and the people who are least likely to get a copy are the peo-
ple who can do something amazing with it, like researchers,” he said. 
Companies are lining up to market products to consumers on the basis 
of their genomes. Law-enforcement agencies 
already use DNA left at crime scenes to find 
suspects and their relatives, and are funding 
programmes to create physical profiles of 
suspects on the basis of their DNA. In other 
words, people now have incomplete pro-
tection for their own DNA, and this lack of 
privacy is likely to increase in the future.
In this free market, how sure can research-
ers be that they are truly doing no harm to their study participants 
when they take a cheek swab? People thinking of entering a study will 
assess the risks of how their volunteered genetic information might 
be used, and this might make them more reluctant to participate. 
Researchers could help to counter this by offering them medically 
relevant information back in exchange. ■
All research studies on humans can uncover facts relevant to a volunteer’s health — at initial screening, during the study itself, or even after the study finishes, when other researchers review 
the data or conduct their own analyses.
For the most part, researchers have opted not to reveal these poten-
tially important ‘incidental findings’ to participants. This has been 
to protect the research process, and to prevent coercing people into 
studies by unwittingly eliciting the ‘therapeutic misconception’ — the 
incorrect assumption on the individual’s part that participating in a 
study will help their own health.
But the emergence of high-throughput genomics, with its ability to 
catalogue vast amounts of information that may have a bearing on a 
person’s health, has prompted a rethink of this convention. 
A working group funded by the US National Institutes of Health 
(NIH) in Bethesda, Maryland, has recommended that biobanks and 
archives that house large genetic data sets introduce policies to encour-
age the return of incidental findings to research subjects (see page 387).
The impact of these recommendations should not be under-
estimated. As genetics invades every branch of medicine, no field is likely 
to be exempt from ethical standards introduced to cover genetic data. 
The recommendations are likely to have their most immediate influ-
ence in discussions on the topic now under way at the US Department 
of Health and the NIH.
There is a precedent for returning information to the subjects of 
a study. In imaging studies, for instance, a radiologist often reviews 
patients’ scans for incidental findings before they are analysed by 
researchers. Support is growing for the idea that genetics researchers 
should similarly review a selected set of genes with known impacts on 
health before undertaking their own research.
Implementing this will not be easy. Defining appropriate sets of genes 
is problematic, and any list will need to be constantly updated. And to 
return the information to an individual in a way that avoids unneces-
sary anxiety and medical expense is a huge issue. Opponents of the idea 
point out that it contravenes standard practice in medicine itself, because 
doctors do not routinely sift through patients’ records for old test results 
that may carry new significance in the light of more recent research. 
Perhaps the most visible example of the need for this debate comes 
not from science, but from commerce. Companies routinely mine vast 
quantities of consumer information to influence marketing decisions. 
Governments have not been able to keep pace with standard business 
practices, and most consumers are unaware of the breadth and depth 
of information that companies gather on them from Internet searches, 
social networks and supermarket purchases.
In testimony before the US Presidential Commission on Bioethics in 
February, John Wilbanks, who runs the project Consent to Research, 
noted that this pattern is likely to repeat itself in the era of electronic 
medical records and genomics. “My sad realization is that whether it’s 
your genome or your health information, anyone who really wants to 
“No field is likely 
to be exempt 
from ethical 
standards 
introduced to 
cover genetic 
data.”
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Need	  Minimal	  Regulatory	  Standards!	  
In	  Choosing	  a	  Sperm	  Donor,	  a	  Roll	  of	  the	  Gene>c	  Dice	  
Sarah	  Phipps	  for	  The	  New	  York	  Times	  
	  
Jaxon	  Kretchmar,	  2,	  who	  was	  conceived	  with	  donated	  sperm,	  has	  cys>c	  fibrosis.	  
	  
Discov	  Med.	  2011	  Jul;12(62):41-­‐55.	  
•  There	  is	  NOTHING	  “Incidental”	  about	  Unrelated	  Findings.	  
	  
•  Sequencing	  a	  bunch	  of	  exomes	  and	  finding	  random	  rare	  variants	  MIGHT	  be	  
“incidental”,	  but	  actually	  proving	  that	  these	  variants	  CAUSE	  the	  disease	  is	  NOT	  
simple	  or	  “incidental”	  or	  “accidental”	  or	  “coincidental”.	  	  
•  I	  would	  suggest	  calling	  these	  “unrelated	  or	  secondary	  findings”,	  rather	  than	  
“incidental”.	  
•  Con>nuing	  to	  call	  these	  “incidental	  findings”	  trivializes	  the	  amount	  of	  work	  that	  
ought	  to	  go	  into	  proving	  causality.	  Lyon,	  Personalized	  Medicine,	  2012.	  
	  
Exome	  sequencing	  of	  one	  pedigree	  in	  
a	  research	  seeng.	  
Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
father and two sons were sequenced. The two sisters in the family 
declined to participate in the study, thus their phenotype status is 
unknown and marked as “?”. 
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Exome	  Sequencing	  performed	  early	  
2010	  
While	  analyzing	  the	  exome	  data,	  research	  par7cipant	  (age	  
~24)	  informs	  me	  that	  he	  recently	  had	  his	  spleen	  removed!	  
	  
He	  has	  idiopathic	  hemoly7c	  anemia,	  since	  childhood.	  
	  
Although	  I	  am	  not	  his	  physician,	  I	  s7ll	  feel	  an	  ethical	  and	  
moral	  obliga7on	  to	  try	  to	  figure	  out	  what	  is	  going	  on.	  
Compound	  Heterozygote	  in	  PKLR,	  with	  
each	  muta>on	  inherited	  from	  one	  
parent.	  
!
Some	  Addi>onal	  Data	  to	  support	  the	  
causa>on	  of	  these	  variants	  for	  
idiopathic	  hemoly>c	  anemia.	  
Structural	  Modeling	  is	  also	  consistent	  with	  deleterious	  effects	  of	  these	  muta>ons.	  
Yet,	  it	  is	  June	  2012	  and	  this	  research	  
par>cipant	  s>ll	  has	  not	  come	  back	  to	  give	  
blood	  for	  CLIA-­‐cer>fied	  results.	  Why?	  
Major	  Barriers	  to	  the	  implementa>on	  of	  Genomic	  Medicine	  in	  
the	  clinic:	  
1)  Lack	  of	  public	  educa>on	  –	  consumer	  not	  sure	  it	  makers.	  
2)  Lack	  of	  physician	  knowledge	  about	  gene>cs.	  
3)  Apathy	  on	  the	  part	  of	  populace,	  as	  they	  have	  “learned”	  to	  be	  
apathe>c	  and	  to	  not	  be	  empowered	  about	  their	  own	  health.	  
4)  Refusal	  of	  insurance	  companies	  to	  pay	  for	  “not	  useful”	  
gene>c	  tes>ng.	  
5)  Focus	  in	  our	  society	  on	  Treatment,	  NOT	  on	  early	  diagnosis	  
and	  preven>on.	  
6)  Societal	  marginaliza>on	  of	  99%	  who	  are	  not	  the	  wealthy	  
elite.	  
Emphasis	  Should	  be	  on	  Diagnosis	  and	  
Preven>on,	  NOT	  just	  on	  Treatment	  
•  15	  year	  old	  girl	  with	  Type	  I	  diabetes,	  hospitalized	  
dozens	  of	  >mes	  with	  diabe>c	  ketoacidosis.	  
Millions	  spent	  to	  save	  life	  repeatedly,	  but	  very	  
likle	  on	  therapy	  or	  educa>on	  –	  WHY?	  
•  14	  year	  old	  boy	  hospitalized	  >10	  >mes	  with	  
pancrea>>s	  over	  >	  ten	  years.	  Finally,	  someone	  
gets	  gene>cs	  consult.	  Pa>ent	  has	  cys>c	  fibrosis,	  
undiagnosed	  >ll	  then.	  Benefits	  from	  pancrea>c	  
enzyme	  supplementa>on,	  plus	  therapy	  and	  
educa>on.	  WHY	  so	  LONG	  to	  diagnose?	  
I	  would	  suggest	  that	  researchers	  working	  on	  DNA	  samples	  
from	  living	  humans	  perform	  CLIA-­‐cer>fied	  sequencing	  UP	  
FRONT,	  either	  with	  exomes	  or	  whole	  genomes,	  so	  that	  we	  can	  
return	  results	  to	  consumers,	  research	  par>cipants	  and	  
families.	  
	  
	  
Secrets	  of	  the	  human	  genome	  disclosed	  
Mee>ng	  debates	  ethics	  of	  revealing	  gene>c	  findings.	  
Erika	  Check	  Hayden	  	  
Published	  online	  4	  October	  2011	  |	  Nature	  478,	  17	  (2011)	  |	  
doi:10.1038/478017a	  	  
	  
	  
Returning	  Results	  and	  Sharing	  Data	  
College	  or	  Funeral	  Is	  Mother’s	  Wish	  Denied	  on	  
DNA	  Results	  
By	  John	  Lauerman	  -­‐	  May	  14,	  2012	  12:01	  AM	  ET	  
Bloomberg	  News	  	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  fissures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  flared	  nares,	  hypoplas>c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
Using Next Gen Seq to figure out genetic basis of a New Disease 
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Family Pedigree 
By	  November	  2010,	  we	  had	  good	  
func>onal	  data	  in	  vitro	  (bacterially	  
expressed	  proteins)	  and	  in	  vivo	  (yeast,	  
unpublished),	  leading	  me	  to	  believe	  
we	  had	  iden>fied	  the	  causa>ve	  
muta>on.	  
	  
A	  new	  mother	  in	  the	  family	  informs	  me	  
she	  is	  4	  months	  pregnant,	  with	  a	  boy!	  
The	  now	  pregnant	  mother-­‐to-­‐be	  is	  circled	  in	  red.	  
Our	  Sanger	  Sequencing	  had	  shown	  her	  to	  be	  a	  
carrier	  of	  the	  muta7on.	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BUT,	  as	  a	  researcher,	  I	  was	  naive	  and	  ignorant	  
concerning	  the	  following	  ques7on:	  
	  
How	  do	  we	  give	  such	  research	  results	  back	  to	  
research	  par7cipants?	  
	  
MAJOR	  ISSUES	  that	  I	  learned	  about	  
•  I	  am	  a	  physician	  but	  not	  HER	  physician,	  therefore	  I	  had	  NOT	  
entered	  into	  a	  “physician-­‐pa>ent	  contract”	  with	  her.	  
•  This	  was	  not	  a	  “diagnos>c	  test”.	  This	  was	  research,	  and	  not	  
“CLIA-­‐cer>fied”.	  All	  Clinical	  Diagnos>c	  Tests	  are	  regulated	  in	  
America	  with	  the	  Clinical	  Laboratory	  Improvement	  
Amendments	  act.	  
	  
•  How	  does	  one	  return	  research	  results	  to	  par>cipants	  without	  
breaking	  the	  law	  or	  doing	  something	  that	  might	  
inadvertently	  harm	  the	  person?	  
•  Please	  remember	  that	  CLIA	  was	  implemented	  to	  prevent	  
people	  from	  being	  given	  wrong	  test	  results	  (due	  to	  poor	  
quality).	  
	  
Societal	  Issues	  
 Test	  tube	  babies	  are	  a	  success	  because	  the	  first	  baby	  born,	  
Louise	  Brown,	  was	  fine	  and	  free	  of	  gene>c	  defects.	  
 Gene	  Therapy	  was	  set	  back	  by	  >10	  years	  due	  to	  the	  death	  of	  
Jesse	  Geisinger	  and	  a	  disregard	  of	  rules	  and	  regula>on	  by	  
certain	  researchers.	  
 We	  have	  Nicholas	  Volcker	  as	  a	  shining	  example	  of	  success	  with	  
WGS.	  
 But,	  we	  don’t	  want	  to	  screw	  this	  up	  with	  some	  research	  lab	  
giving	  back	  incorrect	  results	  to	  someone,	  leading	  to	  some	  
calamitous	  outcome,	  such	  as	  someone	  thinking	  they	  have	  
Hun>ngton’s	  muta>on	  when	  they	  don’t,	  and	  commieng	  
suicide.	  
Technically,	  clinical	  grade	  DNA	  tes7ng	  currently	  means	  the	  
following:	  
	  
1)  Blood	  or	  saliva	  collected	  with	  rigorous,	  automated	  sample	  
tracking.	  
2)  DNA	  isolated	  in	  a	  CLIA-­‐cer>fied	  facility.	  
3)  Sequencing	  performed	  in	  a	  CLIA-­‐cer>fied	  facility.	  
4)  Analysis	  performed	  with	  a	  CLIA-­‐cer>fied	  bioinforma>cs	  pipeline.	  
This	  is	  what	  should	  happen	  with	  any	  sample	  with	  possible	  return	  of	  
results!!!	  
	  
Many	  barriers	  in	  the	  way	  of	  developing	  a	  
test	  at	  ARUP	  (gene>c	  laboratory	  I	  was	  
using	  in	  Utah)	  –	  in	  retrospect,	  should	  have	  
tried	  GeneDx.	  
	  
Mother	  four	  months	  pregnant	  Nov	  2010	  
	  
Baby	  born	  March	  2011.	  
	  
Affected	  with	  Disease.	  
	  
He	  died	  June	  2011,	  same	  week	  as	  
publica>on	  of	  our	  paper	  in	  AJHG.	  
	  
For	  several	  reasons,	  it	  is	  not	  clear	  anything	  
would	  have	  changed	  even	  if	  she	  had	  
received	  the	  result	  during	  pregnancy.	  
	  

Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
What	  about	  the	  other	  women	  in	  the	  family?	  Are	  they	  
carriers?	  Once	  again,	  this	  was	  “research”.	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Results	  from	  Next	  Gen	  Seq	  requires	  
both	  Analy>c	  and	  Clinical	  Validity	  
•  Analy>cal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensi>vity	  and	  specificity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  person?	  
Analy>cal	  Validity	  of	  Exome	  and	  WGS?	  
	  
	  
	  
	  
Minimal	  Standard:	  exomes	  and	  genomes	  ought	  to	  be	  performed	  in	  
a	  CLIA-­‐cer>fied	  environment	  for	  germline	  genomic	  DNA	  from	  live	  
humans	  .	  
	  
Easier	  said	  than	  done	  in	  academia,	  but	  some	  companies	  offer	  this	  
now:	  Illumina,	  23andMe,	  Ambry	  Gene>cs,	  and	  some	  academic	  
places	  do	  offer	  this	  now:	  Baylor	  and	  WashU	  for	  exomes.	  
	  
I	  do	  NOT	  think	  the	  FDA	  should	  get	  involved	  to	  regulate	  this,	  nor	  do	  
the	  results	  have	  to	  go	  through	  a	  physician,	  i.e.	  DTC	  is	  fine	  as	  long	  
as	  CLIA-­‐cer>fied.	  
CLIA-­‐cer>fied	  exomes	  and	  WGS	  
•  The	  CLIA-­‐cer>fied	  pipelines	  akempt	  to	  
minimize	  false	  posi>ves	  with	  increased	  
stringency,	  but	  this	  results	  in	  many	  no-­‐calls	  
and	  other	  areas	  of	  uncertainty,	  which	  should	  
be	  reported	  as	  No-­‐Call	  Regions.	  	  
•  BUT,	  this	  is	  ok,	  as	  minimizing	  false	  posi>ves	  is	  
very	  important	  in	  clinical	  medicine.	  	  
Op>mizing	  Variant	  Calling	  in	  Exomes	  
•  Agilent	  v2	  44	  MB	  exome	  kit	  
•  Illumina	  Hi-­‐Seq	  for	  sequencing.	  
•  Average	  coverage	  ~100-­‐150x.	  
•  Depth	  of	  sequencing	  of	  >80%	  of	  the	  target	  
region	  with	  >20	  reads	  or	  more	  per	  base	  pair.	  
•  Comparing	  various	  pipelines	  for	  alignment	  and	  
variant-­‐calling.	  
SNV	  venn	  plot 
Total	  	  SNP
Total	  	  	  INDEL 
INDEL	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Genomic Dark Matter: The reliability of short read
mapping illustrated by the Genome Mappability Score
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ABSTRACT
Motivation: Genome resequencing and short read mapping are two
of the primary tools of genomics and are used for many important
applications. The current state-of-the-art in mapping uses the quality
values and mapping quality scores to evaluate the reliability of the
mapping. These attributes, however, are assigned to individual
reads and don’t directly measure the problematic repeats across
the genome. Here we present the Genome Mappability Score
(GMS) as a novel measure of the complexity of resequencing a
genome. The GMS is a weighted probability that any read could be
unambiguously mapped to a given position, and thus measures the
overall composition of the genome itself.
Results: We have developed the Genome Mappability Analyzer
(GMA) to compute the GMS of every position in a genome. It
leverages the parallelism of cloud computing to analyze large
genomes, and enabled us to identify the 5-14% of the human,
mouse, fly, and yeast genomes that are difficult to analyze with short
reads. We examined the accuracy of the widely used BWA/SAMtools
polymorphism discovery pipeline in the context of the GMS, and
found discovery errors are dominated by false negatives, especially in
regions with poor GMS. These errors are fundamental to the mapping
process and cannot be overcome by increasing coverage. As such,
the GMS should be considered in every resequencing project to
pinpoint the dark matter of the genome, including of known clinically
relevant variations in these regions.
Availability: The source code and profiles of several model
organisms are available at http://gma-bio.sourceforge.net
Contact: hlee@cs.stonybrook.edu
1 INTRODUCTION
1.1 Background
DNA sequencing technology has dramatically improved in the past
decade so that today an individual human genome can be sequenced
for less than $10,000 and in less then two weeks (Drmanac et al.,
2010), compared to years of effort and hundreds of millions
of dollars for the first sequenced human genome (Stein, 2010).
This dramatic improvement has lead to an exponential growth in
sequencing, including several large projects to sequence thousands
of human genomes and exomes, such as the 1000 Genomes Project
∗to whom correspondence should be addressed
Consortium (2010) or International Cancer Genome Consortium
(2010). Other projects, such as ENCODE Project Consortium
(2004) and modENCODE Consortium (2010) are extensively using
resequencing and read mapping to discover novel genes and binding
sites.
The output of current DNA sequencing instruments consists of
billions of short, 25− 200 base pairs (bp) sequences of DNA called
reads, with an overall per base error rate around 1%-2% (Bentley
et al., 2008). In the case of whole genome resequencing, these
short reads will originate from random locations in the genome,
but nevertheless, entire genomes can be accurately studied by
oversampling the genome, and then aligning or ”mapping” each
read to the reference genome to computationally identify where it
originated. Once the entire collection of reads has been mapped,
variations in the sample can be identified by the pileup of reads that
significantly disagree from the reference genome (Fig. 1).
The leading short read mapping algorithms, including BWA (Li
and Durbin, 2009), Bowtie (Langmead et al., 2009), and SOAP (Li
et al., 2009b), all try to identify the best mapping position for each
read that minimizes the number of differences between the read and
the genome, i.e., the edit distance of the nucleotide strings, possibly
weighted by base quality value. This is made practical through
sophisticated indexing schemes, such as the Burrows-Wheeler
transform (Burrows and Wheeler, 1994), so that many billions of
reads can be efficiently mapped allowing for both sequencing errors
and true variations. The primary complication of short read mapping
is that a read may map equally well or nearly equally well to
multiple positions because of repetitive sequences in the genome.
Notably, nearly 50% of the human genome consists of repetitive
elements, including certain repeats that occur thousands of times
throughout (International Human Genome Sequencing Consortium,
2001).
For resequencing projects, the fraction of repetitive content
depends on read length and allowed error rate. At one extreme, all
single base reads would be repetitive, while chromosome length
reads would not be repetitive at all. Similarly, increasing the
allowed error rate increases the fraction of the genome that is
repetitive. The short read mapping algorithms use edit distance and
other read characteristics to compute a mapping quality score for
each mapped read (Li et al., 2008). The mapping quality score
estimates the probability that the assigned location is the correct
1
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oversampling the genome, and then aligning or ”mapping” each
read to the reference genome to computationally identify where it
originated. Once the entire collection of reads has been mapped,
variations in the sample can be identified by the pileup of reads that
significantly disagree from the reference genome (Fig. 1).
The leading short read mapping algorithms, including BWA (Li
and Durbin, 2009), Bowtie (Langmead et al., 2009), and SOAP (Li
et al., 2009b), all try to identify the best mapping position for each
read that minimizes the number of differences between the read and
the genome, i.e., the edit distance of the nucleotide strings, possibly
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2001).
For resequencing projects, the fraction of repetitive content
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reads would not be repetitive at all. Similarly, increasing the
allowed error rate increases the fraction of the genome that is
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other read characteristics to compute a mapping quality score for
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 Genome	  Mappability	  Score	  (GMS)	  -­‐-­‐	  measure	  of	  the	  complexity	  of	  resequencing	  a	  
genome	  =	  a	  weighted	  probability	  that	  any	  read	  could	  be	  unambiguously	  mapped	  to	  a	  
given	  p si>on,	  and	  thus	  measures	  the	  overall	  composi>on	  of	  the	  genome	  its lf.	  
 Genome	  Mappability	  An lyzer	  (GMA)	  -­‐-­‐	  to	  compute	  the	  GMS	  of	  every	  posi>o 	  in	  a	  
genome.	  Helps	  iden>fy	  the	  5-­‐ 4%	  of	  the	  human,	  mouse,	  fly,	  and	  yeast	  genomes	  that	  are	  
difficult	  to	  analyze	  with	  short	  reads.	  	  
 With	  BWA/SAMtools	  poly orphism	  discovery	  pipeline,	  discovery	  errors	  are	  dominated	  
by	  false	  nega>ves,	  especially	  in	  regions	  with	  poor	  GMS.	  These	  errors	  are	  fundamental	  to	  
the	  mapping	  process	  and	  cannot	  be	  overcome	  by	  increasing	  coverage.	  	  
 The	  GMS	  should	  be	  considered	  in	  every	  resequencing	  project	  to	  pinpoint	  the	  dark	  
maker	  of	  the	  g nome,	  in ludi g	   f	  known	  clinic lly	  rel vant	  varia>ons	  in	  these	  regions.	  
Hype	  and	  Gene>c	  Determinism	  
•  “The	  ability	  to	  noninvasively	  sequence	  a	  fetal	  
genome	  to	  high	  accuracy	  and	  completeness	  
will	  undoubtedly	  have	  profound	  implica>ons	  
for	  the	  future	  of	  prenatal	  gene>c	  diagnos>cs.”	  
•  Yes,	  but	  this	  is	  NOT	  that	  study!	  
GENOMICS
Noninvasive Whole-Genome Sequencing of a
Human Fetus
Jacob O. Kitzman,1* Matthew W. Snyder,1 Mario Ventura,1,2 Alexandra P. Lewis,1 Ruolan Qiu,1
LaVone E. Simmons,3 Hilary S. Gammill,3,4 Craig E. Rubens,5,6 Donna A. Santillan,7
Jeffrey C. Murray,8 Holly K. Tabor,5,9 Michael J. Bamshad,1,5 Evan E. Eichler,1,10 Jay Shendure1*
Analysis of cell-free fetal DNA in maternal plasma holds promise for the development of noninvasive prenatal
genetic diagnostics. Previous studies have been restricted to detection of fetal trisomies, to specific paternally
inherited mutations, or to genotyping common polymorphisms using material obtained invasively, for example,
through chorionic villus sampling. Here, we combine genome sequencing of two parents, genome-wide maternal
haplotyping, and deep sequencing of maternal plasma DNA to noninvasively determine the genome sequence
of a human fetus at 18.5 weeks of gestation. Inheritance was predicted at 2.8 × 106 parental heterozygous sites
with 98.1% accuracy. Furthermore, 39 of 44 de novo point mutations in the fetal genome were detected, albeit
with limited specificity. Subsampling these data and an lyzing a second family trio by the same approach in-
dicate that parental haplotype blocks of ~300 kilo–base pairs combined with shallow sequencing of maternal
plasma DNA is sufficient to substantially determine the inherited complement of a fetal genome. However,
ultradeep sequencing of maternal plasma DNA is necessary for the practical detection of fetal de novo mutations
genome-wide. Although technical and analytical challenges remain, we anticipate that noninvasive analysis of
inherited variation and de novo mutations in fetal genomes will facilitate prenatal diagnosis of both recessive
and dominant Mendelian disorders.
INTRODUCTION
On average, ~13% of cell-free DNA isolated frommaternal plasma dur-
ing pregnancy is fetal in origin (1). The concentration of cell-free fetal
DNA in the maternal circulation varies between individuals, increases
during gestation, and is rapidly cleared postpartum (2, 3). Despite this
variability, cell-free fetal DNA has been successfully targeted for non-
invasive prenatal diagnosis including for development of targeted assays
for single-gene disorders (4). More recently, several groups have dem-
onstrated that shotgun,massively parallel sequencing of cell-freeDNA
from maternal plasma is a robust approach for noninvasively diag-
nosing fetal aneuploidies such as trisomy 21 (5, 6).
Ideally, it should be possible to noninvasively predict the whole-
genome sequence of a fetus to high accuracy and completeness, poten-
tially enabling the comprehensive prenatal diagnosis of Mendelian
disorders and obviating the need for invasive prenatal diagnostic proce-
dures such as chorionic villus samplingwith their attendant risks. How-
ever, several key technical obstacles must be overcome for this goal to
be achieved using cell-freeDNA frommaternal plasma. First, the sparse
representationof fetal-derived sequences poses the challenge of detecting
low-frequency alleles inherited from the paternal genomeaswell as those
arising from de novomutations in the fetal genome. Second,maternal
DNApredominates in themother’s plasma,making it difficult to assess
maternally inherited variation at individual sites in the fetal genome.
Recently, Lo et al. showed that fetal-derived DNA is distributed
sufficiently evenly in maternal plasma to support the inference of fetal
genotypes, and furthermore, they demonstrated how knowledge of
parental haplotypes could be leveraged to this end (7). However, their
study was limited in several ways. First, the proposedmethod depended
on the availability of parental haplotypes, but at the time of their work,
no technologies existed to measure these experimentally on a genome-
wide scale. Therefore, an invasive procedure, chorionic villus sampling,
was used to obtain placental material for fetal genotyping. Second, pa-
rental genotypes and fetal genotypes obtained invasively were used to
infer parental haplotypes. These haplotypes were then used in combi-
nation with the sequencing of DNA from maternal plasma to predict
the fetal genotypes. Although necessitated by the lack of genome-wide
haplotyping methods, the circularity of these inferences makes it diffi-
cult to assess how well the method would perform in practice. Third,
their analysis was restricted to several hundred thousand parentally het-
erozygous sites of common single-nucleotide polymorphisms (SNPs)
represented on a commercial genotyping array. These common SNPs
are only a small fraction of the severalmillion heterozygous sites present
in each parental genome and include few of the rare variants that pre-
dominantly underlie Mendelian disorders (8). Fourth, Lo et al. did not
ascertain de novo mutations in the fetal genome. Because de novo mu-
tations underlie a substantial fraction of dominant genetic disorders,
their detection is critical for comprehensive prenatal genetic diagnostics.
Therefore, although the Lo et al. study demonstrated the first successful
construction of a genetic map of a fetus, it required an invasive proce-
dure and did not attempt to determine the whole-genome sequence
of the fetus. We and others recently demonstrated methods for exper-
imentally determining haplotypes for both rare and common variation
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Actual	  Data	  
•  “we	  found	  2.5	  ×	  107	  candidate	  de	  novo	  sites,	  
including	  39	  of	  the	  44	  true	  de	  novo	  sites.	  At	  
baseline,	  this	  corresponds	  to	  sensi>vity	  of	  88.6%	  
with	  a	  signal-­‐	  to-­‐noise	  ra>o	  of	  1-­‐to-­‐640,000”	  
•  With	  other	  filters,	  they	  reduce	  number	  of	  “total	  
posi>ves”	  to	  3884,	  of	  which	  17	  are	  true	  posi>ves,	  
from	  total	  known	  true	  posi>ves	  of	  44),	  so	  
sensi>vity=	  38.6%.	  
•  This	  is	  nowhere	  near	  accurate,	  or	  anything	  
remotely	  close	  to	  a	  clinical	  grade	  test!	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  way	  
forward	  is	  with	  a	  “networking	  of	  
science”	  model.	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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWK D 0$)   
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
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As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
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More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio ? 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
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hours after birth, and the infant was admitted to
the neonatal ward for assessment. He appeared ex-
traordinarily muscular, with protruding muscles
in his thighs (Fig. 1A) and upper arms. With the
exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
 
2
 
), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
ported to be unusually strong. Family member II-3
was a construction worker who was able to unload
curbstones by hand. The 24-year-old mother of the
child (III-5) appeared muscular, though not to the
extent observed in her son; she did not report any
health problems. No family members aside from
the mother were available to provide samples for
genetic analysis.
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
 
The arrowheads in Panel A indicate the protruding mus-
cles of the patient’s thigh and calf. In Panel B, an ultra-
sonographic transverse section (linear transducer, 10 
MHz) through the middle portion of the thigh reveals 
differences between the patient and a control infant of 
the same age, sex, and weight. VL denotes vastus latera-
lis, VI vastus intermedius, VM vastus medialis, RF rectus 
femoris, and F femur. In Panel C, retracings of the mus-
cle outlines and results of the morphometric analysis of 
the muscle cross-sectional planes of the two infants also 
reveal marked differences. Panel D shows the patient’s 
pedigree. Solid symbols denote family members who are 
exceptionally strong, according to information in their 
clinical history. Square symbols denote male family 
members, and circles female family members.
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uscle wasting and weakness are among the most common
 
 
 
in-
 
herited and acquired disorders and include the muscular dystrophies,
cachexia, and ag -related wasting. Since there is no generally accepted
treatment to i prove muscle bulk and strength, these conditions pose a substantial
burden to patients as well as to public health. Consequently, there has been consider-
able interest in a recently described inhibitor of muscle growth, myostatin, or growth/
differentiation factor 8 (GDF-8), which belongs to the transforming growth factor 
 
b
 
superfamily of secreted proteins that control the growth and differentiation of tissues
throughout the body. The myostatin gene is expressed almost exclusively in cells of
skeletal-muscle lineage throughout embryonic development as well as in adult ani-
mals and functions as a negative regulator of muscle growth.
 
1,2
 
 Targeted disruption of
the myostatin gene in mice doubles skeletal-muscle mass.
 
1
 
 Conversely, systemic over-
expression of the myostatin gene leads to a wasting syndrome characterized by ex-
tensive muscle loss.
 
3
 
 In adult animals, myostatin appears to inhibit the activation of
satellite cells, which are stem cells resident in skeletal muscle.
 
4,5
 
The potential relevance of myostatin to the treatment of disease in humans has been
suggested by studies involving 
 
mdx
 
 mi e, which carry a mutation in the dystrophin gene
and therefore serve as a genetic model of Duchenne’s and Becker’s muscular dystro-
phy.
 
6
 
 For example
 
, mdx
 
 mice that lacke  myost tin were foun  not only to be stronger
and more muscular than their
 
mdx
 
 counterparts with normal myostatin, but also to have
reduced fibrosis and fatty remodeling, suggesting mproved regeneration of us-
cle.
 
7
 
 Furthermore, injection of neutralizing monoclonal antibodies directed against
myostatin into either wild-type or 
 
mdx
 
 mice increases mus le mass and specific force,
suggesting that myostatin plays an important role in regulating muscle growth in adult
animals.
 
8,9
 
The function of myostatin appears to be conserved across species, since mutations
in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th percentile. Stimulus-induced myoclonus developed several
m
case report
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in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th p rcentile. Stimulus-induced myoclonus developed several
m
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Double muscling is a trait previously described in several mammalian species including cattle and sheep and is caused
by mutations in the myostatin (MSTN) gene (previously referred to as GDF8). Here we describe a new mutation inMSTN
found in the whippet dog breed that results in a double-muscled phenotype known as the ‘‘bully’’ whippet. Individuals
with this phenotype carry two copies of a two-base-pair deletion in the third exon ofMSTN leading to a premature stop
codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
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Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  
expressivity	  of	  ANY	  muta>ons	  in	  humans,	  as	  we	  
have	  not	  systema>cally	  sequenced	  or	  karyotyped	  
any	  gene>c	  altera>on	  in	  MILLIONS	  of	  people,	  nor	  
categorized	  into	  ethnic	  classes,	  i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  does	  
gene>cs	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modified	  substan>ally	  by	  environment?	  
i.e.	  is	  there	  really	  such	  a	  thing	  as	  gene>c	  
determinism	  for	  MANY	  muta>ons?	  
For	  now,	  more	  effort	  should	  be	  placed	  
on	  the	  following:	  
•  Rare,	  highly	  penetrant	  muta>ons	  running	  in	  
families,	  with	  cascade	  carrier	  tes>ng.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some>mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  know	  much	  more	  about	  issues	  
with	  penetrance	  of	  rare	  variants	  in	  these	  families.	  
Pandora’s	  Baby	  
•  “It	  seemed	  to	  boil	  down	  to	  a	  struggle	  between	  
two	  compe>ng	  impulses:	  the	  crea>ve	  drive	  to	  
understand	  nature	  versus	  the	  conserva>ve	  
drive	  to	  impose	  limits	  and	  maintain	  the	  status	  
quo.”	  
Autonomy	  vs.	  Privacy	  vs.	  Bureaucracy	  
Privacy	  
Autonomy	  
Bureaucracy	  
Vanderbilt	  	  	  	  	  	  CHOP	  	  	  	  	  ClinSeq-­‐NIH	  	  	  	  	  Gene	  Partnership	  	  	  	  	  Personal	  Genome	  Project	  	  	  	  Pa7entsLikeMe	  
	   	   	   	   	   	   	   	   	   	   	  23AndMe	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Ancestry.com	  
Killing	  Innova>on	  with	  Bureaucracy	  
•  These	  are	  NOT	  evil	  people,	  but	  rather	  very	  
cau>ous	  people.	  
•  Endless	  mee>ngs	  at	  FDA	  and	  CMS,	  which	  
takes	  substan>al	  >me.	  
•  People	  become	  used	  to	  the	  system	  within	  
which	  they	  func>on,	  making	  it	  very	  difficult	  for	  
them	  to	  envision	  changing	  the	  status	  quo.	  
	  
An	  alternate	  universe	  
•  Genomes	  sequenced	  by	  companies	  and	  academics	  with	  the	  
minimal	  standards	  in	  place	  (i.e.	  CLIA	  in	  America).	  
•  All	  data,	  including	  variant	  lists,	  added	  to	  “the	  cloud”	  that	  
consumers	  can	  access.	  
•  Consumers	  can	  go	  back	  and	  repeatedly	  look	  at	  their	  own	  
genome.	  
•  Consumers	  own	  and	  manage	  these	  data,	  and	  they	  can	  pay	  
anyone	  they	  like	  to	  help	  them	  interpret	  the	  data	  for	  them.	  
•  These	  are	  CONSUMERS,	  not	  pa>ents,	  and	  we	  need	  to	  move	  
away	  from	  paternalis7c	  medicine.	  
•  I	  am	  concerned	  that	  regula>on	  requiring	  delivery	  of	  gene>c	  
data	  by	  “physicians”	  will	  choke	  off	  and	  kill	  the	  genomic	  
revolu>on	  and	  individualized	  medicine.	  
One	  Solu>on	  
•  Require	  that	  all	  ini7al	  germline	  exome	  and	  whole	  genome	  
sequencing	  in	  live	  humans	  be	  performed	  in	  a	  CLIA-­‐cer>fied	  or	  
other	  clinical-­‐grade	  manner.	  
•  I	  pray	  and	  hope	  that	  industry	  will	  collate	  and	  distribute	  
muta>ons	  in	  an	  interna>onal	  human	  varia>on	  database,	  
allowing	  for	  calcula>on	  of	  penetrance	  and	  extensive	  burden	  
tes>ng.	  
•  CLIA-­‐cer>fied	  (clinical	  grade)	  sequencing	  up	  front	  allows	  
return	  of	  all	  data,	  including	  rare,	  highly	  penetrant	  muta>ons,	  
to	  families,	  facilita>ng	  carrier	  screening	  and	  counseling.	  
•  Require	  return	  of	  genomic	  data	  to	  par>cipants,	  allowing	  the	  
par>cipants	  to	  distribute	  and	  “crowd-­‐source”	  their	  own	  data.	  
•  Government	  should	  divert	  funds	  toward	  a	  10	  to	  100	  fold	  
increase	  for	  gene>c	  counselors,	  so	  that	  we	  can	  have	  
compassionate	  engagement	  with	  families.	  
Ancestry.com	  meets	  23andMe	  meets	  
Pa>entsLikeMe	  meets	  Illumina?	  
Clinical	  Validity	  with	  Worldwide	  
Human	  Gene>c	  Varia>on	  “database”?	  
Pa7entsLikeMe	  
Need	  to	  change	  the	  Tenor	  of	  the	  
debate	  
•  Evolving	  ethics.	  
•  Sequencing	  live	  humans	  without	  method	  in	  place	  to	  return	  
results,	  perhaps	  no	  longer	  acceptable?	  	  
•  These	  are	  human	  beings,	  not	  “pa>ents”.	  PLEASE	  get	  rid	  of	  
this	  paternalism!!!	  And	  get	  rid	  of	  this	  term	  “pa>ent”!	  
•  “What	  kind	  of	  work	  deemed	  as	  accepted	  today	  will	  be	  
denounced	  by	  future	  genera>ons?	  The	  ques>on	  is	  one	  that	  
all	  researchers	  should	  bear	  in	  mind,	  because	  history	  may	  
judge	  them	  more	  harshly	  than	  their	  peers	  do.”	  
-­‐Nature	  editorial,	  February	  9,	  2012	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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•  @Katy_Read:	  Like	  many	  writers,	  I	  have	  rituals.	  
Before	  wri>ng,	  I	  pour	  some	  coffee,	  open	  the	  
window	  by	  my	  desk,	  and	  akempt	  to	  read	  the	  
en>re	  internet.	  
